AbstractWe have studied the population dynamics in response to selective drug pressure of mixtures of wild-type and mutant HIV viruses exposed to either an inhibitor of the viral protease or a nonnucleoside allosteric inhibitor of the viral reverse transcriptase. In order to quantitate mutant virus present in a mixed population, we developed a selective plaque assay, which appears to be generally applicable to population dynamics studies where the viruses in question differ in the sensitivity to a given drug by at least 10-fold. In this assay system, the titer of virus in a mixture is measured in the absence and presence of a concentration of a specific inhibitor known to suppress virus replication by 99%. Virus detected in the presence of ...
Treatment of human immunodeficiency virus type 1 (HIV-1) infection during the clinical latency phase...
The human immunodeficiency virus (HIV) is the primary etiologic agent of the acquired immunodeficien...
Inhibitors of the human immunodeficiency virus (HIV) protease are a promising class of antiviral age...
AbstractWe have studied the population dynamics in response to selective drug pressure of mixtures o...
Anti!viral drug treatment of infections with the human immunode_ciency virus type 0 "HIV!0 # us...
Antiretroviral therapy (ARV) exert a selective pressure on HIV-1 and may select viral drug resistant...
Evolution and transmission of multiply drug-resistant human immunodeficiency virus type 1 (HIV-1) ma...
Objectives: To study the effect of the interruption of reverse transriptase inhibitor (RTI) therapy ...
We studied the intrahost evolution and dynamics of a multidrug-resistant HIV-1, which contains an in...
Background: Effectiveness of ART regimens strongly depends upon complex interactions between the sel...
Supplementary text S1 for Pennings, P.S., Standing genetic variation and the evolution of drug resis...
Particularly for therapy-experienced patients, resistance assessment by genotypic or phenotypic meth...
Nevirapine forms the mainstay of our efforts to curtail the pediatric AIDS epidemic through preventi...
Treatment of HIV-1 infection with 3'-azido-2',3'-dideoxythymidine (AZT) frequently results in the ev...
<div><p>Despite the success of highly active antiretroviral therapy (HAART) in the management of hum...
Treatment of human immunodeficiency virus type 1 (HIV-1) infection during the clinical latency phase...
The human immunodeficiency virus (HIV) is the primary etiologic agent of the acquired immunodeficien...
Inhibitors of the human immunodeficiency virus (HIV) protease are a promising class of antiviral age...
AbstractWe have studied the population dynamics in response to selective drug pressure of mixtures o...
Anti!viral drug treatment of infections with the human immunode_ciency virus type 0 "HIV!0 # us...
Antiretroviral therapy (ARV) exert a selective pressure on HIV-1 and may select viral drug resistant...
Evolution and transmission of multiply drug-resistant human immunodeficiency virus type 1 (HIV-1) ma...
Objectives: To study the effect of the interruption of reverse transriptase inhibitor (RTI) therapy ...
We studied the intrahost evolution and dynamics of a multidrug-resistant HIV-1, which contains an in...
Background: Effectiveness of ART regimens strongly depends upon complex interactions between the sel...
Supplementary text S1 for Pennings, P.S., Standing genetic variation and the evolution of drug resis...
Particularly for therapy-experienced patients, resistance assessment by genotypic or phenotypic meth...
Nevirapine forms the mainstay of our efforts to curtail the pediatric AIDS epidemic through preventi...
Treatment of HIV-1 infection with 3'-azido-2',3'-dideoxythymidine (AZT) frequently results in the ev...
<div><p>Despite the success of highly active antiretroviral therapy (HAART) in the management of hum...
Treatment of human immunodeficiency virus type 1 (HIV-1) infection during the clinical latency phase...
The human immunodeficiency virus (HIV) is the primary etiologic agent of the acquired immunodeficien...
Inhibitors of the human immunodeficiency virus (HIV) protease are a promising class of antiviral age...